Japan Approves Astellas/Kotobuki SGLT2 Inhibitor Suglat
This article was originally published in PharmAsia News
Executive Summary
Japan drug authorities have approved the nation's first SGLT2 inhibitor Suglat for type 2 diabetes drugs from Astellas and Kotobuki.